Press Release
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer’s Disease Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.
About Product ZUNVEYL
ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.
About Alzheimer’s Disease
Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.
Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.
On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.
Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.
Reference:
- Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832
- Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-ther…
- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.1003
- 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004
- Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7
- Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.
- Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-diseas…
- Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html
- Data on patient discontinuation as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source: China Medical System Holdings Ltd.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Pear Protocol Goes Live with Hyperliquid Integration and Announces $4.1M Strategic Round Led by Castle Island Ventures
London, UK, 28th July 2025, ZEX PR WIRE, Pear Protocol, the premier pair trading platform in crypto, has officially launched its native integration with Hyperliquid, unlocking seamless pair trading on top of the Hyperliquid perpetual orderbook.
This launch coincides with the closing of a $4.1M strategic funding round led by Castle Island Ventures, with participation from Compound VC, Florin Digital and Sigil Fund. The raise comes as Pear Protocol nears $1BN in trading volume, powering over 4,000 traders with daily volumes in closed beta already above $5M+.
“Hyperliquid is where the best traders are, and Pear now provides the best way to pair trade on top of that liquidity,” said Huf, Founder of Pear Protocol. “This round marks a turning point – our investors deeply understand the space, and together we’re going full throttle on execution.”
What This Means for Users
With the Hyperliquid integration now live, traders on Pear can enjoy:
- Continued eligibility for any Hyperliquid Season 3 points and HyPear Points, converting into claimable $HYPE
- One-click entry and exit across both legs of a pair trade
- Limit and TWAP execution on the ratio, optimising entry and exits
- TP/SL logic based on the ratio for superior risk management
- Direct ratio charting, net funding differentials, and custom pair weighting tools
Pear makes advanced strategies simple, mobile-friendly, and capital-efficient – whether you’re trading HYPE/SOL or building custom ETH/BTC trades with beta-weighted logic.
Strategic Use of Funds
The new capital will be deployed to:
- Expand Pear’s institutional-grade product suite
- Launch vaults and APIs on HyperEVM
- Re-launch their spot token with deeper liquidity on Hyperliquid’s Spot Orderbook
- Accelerate user growth and talent acquisition
- Position Pear for long-term sustainability – including optional protocol buybacks and new revenue lines
This round strategically aligns Pear Protocol with some of the most respected players in crypto venture, each bringing ecosystem reach, product insight, and long-term conviction.
“We believe Pear is building trading infrastructure for the next wave of DeFi-native professionals,” said Wyatt Khosrowshahi, Investor at Castle Island Ventures. “They’re connecting deep crypto-native liquidity with intuitive UX, timely education, and novel execution.”
About Pear Protocol
Pear Protocol is the leading DeFi-native pair trading terminal, enabling users to trade one token against another with high capital efficiency. With integrations across major venues including Hyperliquid, GMX and SYMMIO, Pear serves both professional retail and institutional users. Learn more at https://pear.garden
Check out Pear’s Launch Video Here – https://youtu.be/WF8kF1FRxSU
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Israel, 28th Jul 2025, –
The Art of Managing Humans: Management Practices That Actually Work by Tsvika Abramovitch has been awarded the Book Excellence Award, recognizing its unique, experience-driven approach to leadership, human resources, and organizational culture. The award, presented by OneTribune Media, celebrates literary excellence in storytelling, creativity, and global impact.
A seasoned HR executive with decades of experience across some of Israel’s largest organizations, Abramovitch brings practical insight and authentic field-tested wisdom to a discipline often crowded with theory. With candor and clarity, The Art of Managing Humans challenges leaders to rethink their assumptions about power, loyalty, and culture in the modern workplace.
A Real-World Guide to Managing with Empathy and Balance
As the OneTribune Media reviewer puts it: “What do playground equipment and office politics have in common? Quite a lot, if you ask Tsvika Abramovitch. In The Art of Managing Humans, the metaphor of a seesaw isn’t just clever—it’s profoundly insightful.”
Rather than relying on formulas or clichés, Abramovitch shares “lived experience—warts and all—gleaned from decades in HR trenches,” turning stories of boardroom negotiations, crisis management, and team development into practical tools.
At the center of the book is the Seesaw Model—a deceptively simple but powerful framework that reframes leadership as a constant balancing act: “part organizational strategy, part emotional compass.” Through tools like roundtable discussions, field trips, and one-on-one check-ins, the model emphasizes transparency, trust, and human-centered decision-making.
This approach avoids rigid, top-down models. Instead, it encourages leaders to “lead not from a distance, but from within, setting boundaries without barricades and making transparency a habit, not a performance.”
An earlier review from HR for Humans at Work describes the book as “a fresh approach to leadership, showing how fostering authentic relationships, transparency, and open communication between managers and employees can drive organisational success.” The review praises Abramovitch’s focus on people-first leadership, calling The Art of Managing Humans a “people-centric management blueprint” grounded in real-world experience. It compares Abramovitch’s perspective to the leadership philosophy of Howard Schultz. Ultimately, the reviewer calls the book “a must-read for leaders seeking to humanise their approach,” offering “the warmth and wisdom needed to transform any organisation.”
More details about this announcement can be found on the OneTribune Media website.
About the Award
The Book Excellence Award is given to works that demonstrate superior quality in writing, presentation, and impact. More than a symbol of professional merit, it honors books that “inspire, inform, and transform readers across the globe.” The Art of Managing Humans was recognized for its exceptional blend of storytelling, practical insight, and meaningful contribution to the conversation on modern leadership.
About the Book
Title: The Art of Managing Humans: Management Practices That Actually Work
Author: Tsvika Abramovitch
Availability: Amazon and major online retailers
Genre: Business / Management
Sub-genres: Human Resources, Organizational Psychology, Workplace Strategy
Themes: Leadership through empathy, transparency, emotional intelligence, real-world HR solutions, employee loyalty, and the balance of power
About the Author
Tsvika Abramovitch is a senior human resource strategist and leadership advisor with more than 30 years of experience. He has held executive HR positions at top-tier Israeli companies including Bezeq International, Pelephone, Yes, Tnuva, Mekorot, and Hadera Paper. Known for bridging strategy and emotional intelligence, he developed the Seesaw Model to help organizations navigate the evolving challenges of people management. The Art of Managing Humans is his debut book, now recognized for excellence in business writing.
Media Contact
Organization: Author of The Art of Managing Humans
Contact
Person: Tsvika Abramovitch
Email:
tsvikabr@pelephone.co.il
Country:Israel
The post
The Art of Managing Humans by Tsvika Abramovitch Receives Book Excellence Award appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Israel, 28th Jul 2025, –
The Art of Managing Humans: Management Practices That Actually Work by Tsvika Abramovitch has been awarded the Book Excellence Award, recognizing its unique, experience-driven approach to leadership, human resources, and organizational culture. The award, presented by OneTribune Media, celebrates literary excellence in storytelling, creativity, and global impact.
A seasoned HR executive with decades of experience across some of Israel’s largest organizations, Abramovitch brings practical insight and authentic field-tested wisdom to a discipline often crowded with theory. With candor and clarity, The Art of Managing Humans challenges leaders to rethink their assumptions about power, loyalty, and culture in the modern workplace.
A Real-World Guide to Managing with Empathy and Balance
As the OneTribune Media reviewer puts it: “What do playground equipment and office politics have in common? Quite a lot, if you ask Tsvika Abramovitch. In The Art of Managing Humans, the metaphor of a seesaw isn’t just clever—it’s profoundly insightful.”
Rather than relying on formulas or clichés, Abramovitch shares “lived experience—warts and all—gleaned from decades in HR trenches,” turning stories of boardroom negotiations, crisis management, and team development into practical tools.
At the center of the book is the Seesaw Model—a deceptively simple but powerful framework that reframes leadership as a constant balancing act: “part organizational strategy, part emotional compass.” Through tools like roundtable discussions, field trips, and one-on-one check-ins, the model emphasizes transparency, trust, and human-centered decision-making.
This approach avoids rigid, top-down models. Instead, it encourages leaders to “lead not from a distance, but from within, setting boundaries without barricades and making transparency a habit, not a performance.”
An earlier review from HR for Humans at Work describes the book as “a fresh approach to leadership, showing how fostering authentic relationships, transparency, and open communication between managers and employees can drive organisational success.” The review praises Abramovitch’s focus on people-first leadership, calling The Art of Managing Humans a “people-centric management blueprint” grounded in real-world experience. It compares Abramovitch’s perspective to the leadership philosophy of Howard Schultz. Ultimately, the reviewer calls the book “a must-read for leaders seeking to humanise their approach,” offering “the warmth and wisdom needed to transform any organisation.”
More details about this announcement can be found on the OneTribune Media website.
About the Award
The Book Excellence Award is given to works that demonstrate superior quality in writing, presentation, and impact. More than a symbol of professional merit, it honors books that “inspire, inform, and transform readers across the globe.” The Art of Managing Humans was recognized for its exceptional blend of storytelling, practical insight, and meaningful contribution to the conversation on modern leadership.
About the Book
Title: The Art of Managing Humans: Management Practices That Actually Work
Author: Tsvika Abramovitch
Availability: Amazon and major online retailers
Genre: Business / Management
Sub-genres: Human Resources, Organizational Psychology, Workplace Strategy
Themes: Leadership through empathy, transparency, emotional intelligence, real-world HR solutions, employee loyalty, and the balance of power
About the Author
Tsvika Abramovitch is a senior human resource strategist and leadership advisor with more than 30 years of experience. He has held executive HR positions at top-tier Israeli companies including Bezeq International, Pelephone, Yes, Tnuva, Mekorot, and Hadera Paper. Known for bridging strategy and emotional intelligence, he developed the Seesaw Model to help organizations navigate the evolving challenges of people management. The Art of Managing Humans is his debut book, now recognized for excellence in business writing.
Media Contact
Organization: Author of The Art of Managing Humans
Contact
Person: Tsvika Abramovitch
Email:
tsvikabr@pelephone.co.il
Country:Israel
The post
The Art of Managing Humans by Tsvika Abramovitch Receives Book Excellence Award appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Pear Protocol Goes Live with Hyperliquid Integration and Announces $4.1M Strategic Round Led by Castle Island Ventures
The Art of Managing Humans by Tsvika Abramovitch Receives Book Excellence Award
Winners Announced for The World’s Best Awards 2025
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Microsoft License Enables Organizations to Navigate the Evolving Digital Landscape Through Customized Microsoft Solutions
-
Press Release3 days ago
RI Mining Takes Advantage of the Global XRP Craze to Open a New Era of AI Cloud Mining – Allowing Your Digital Assets to Change from Passive to Active at Any Time
-
Press Release7 days ago
Accounting AI Collaboration Aims to Transform Military Accounting Efficiency in Southeast Asia
-
Press Release7 days ago
Hotel Campaign by MCANISM Reaches New Heights with SKYNET Milestone Success
-
Press Release7 days ago
DigiPay Guru Expands to Africa with Its Next-Gen Mobile Money Solution to Drive Financial Inclusion
-
Press Release7 days ago
How the Grand Time Fund Was Created
-
Press Release6 days ago
Stage Point Europe Launches Its RWA Token $SPET, Setting it up as a Bridge Between Crypto and Real Estate
-
Press Release6 days ago
Crypto Investors Earn $5,777/Day on BAY Miner with BTC and XRP Gains
-
Press Release6 days ago
Education Edge Strengthens Canadas PMP Training Landscape with Proven Certification Success